发现了第一个BRD4第二原体 (BD2) -选择性抑制剂
Junhua Li1, Qingqing Hu1, Run Zhu1,2
1China-New Zealand Joint Laboratory of Biomedicine and Health, State Key Laboratory of Respiratory Disease, Guangdong Provincial Key Laboratory of Biocomputing, Institute of Drug Discovery, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, No. 190 Kaiyuan Avenue, Guangzhou 510530, China.
Journal of medicinal chemistry
|November 27, 2024
概括
研究人员开发了首个向BRD4 BD2蛋白的选择性抑制剂,为表观遗传学研究提供了有前途的进步,并可能减少白血病治疗中的非向毒性.
科学领域:
- 药用化学 医学化学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 癌症研究 癌症研究
背景情况:
- 泛BET抑制剂表现出抗白血病作用,但可能导致剂量限制性毒性.
- 抑制多个BETBD2蛋白质引发了对非目标毒性的担忧.
- 需要对特定的BET家族域进行选择性抑制.
研究的目的:
- 为了确定第一个选择性抑制剂的odomain 4 (BRD4) BD2域.
- 与泛BD2抑制剂相比,开发一种具有提高选择性和减少目标外影响的化合物.
主要方法:
- 基于结构的药物设计,使用以前的泛BD2抑制剂 (XY153).
- 生物化学测试以确定结合亲和力 (IC50) 和选择性 (折叠选择性).
- 生物层干扰测量 (BLI) 试验以确认域选择性.
- 在体外测定肝脏微体稳定性和药理动力学概况.
主要成果:
- 确定化合物16o (XY221) 作为第一个BRD4BD2选择性抑制剂.
- 16o证明强烈结合BRD4BD2 (IC50=5.8nM) 的情况.
- 实现了高选择性:比BRD4BD1高667倍,比其他BETBD2领域高9至32倍;在BLI试验中,选择性为66至144倍.
- 表现出有利的肝脏微体稳定性 (T1/2 > 120 分钟) 和药物动力学特性 (F = 13.1%).
结论:
- 化合物16o作为第一个BRD4BD2选择性抑制剂,代表了重要的进步.
- 它的高选择性和有利的类似药物的特性使其成为表观遗传学研究的宝贵工具.
- 16o具有作为癌症治疗,特别是白血病进一步发展的候选人潜力.
相关概念视频
Drug Discovery: Overview
7.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
7.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Electrophilic 1,2- and 1,4-Addition of X2 to 1,3-Butadiene
2.4K
Electrophilic addition of halogens to alkenes proceeds via a cyclic halonium ion to form a 1,2-dihalide or a vicinal dihalide.
2.4K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Structure-Activity Relationships and Drug Design
595
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
595


